Researchers have developed a metric called IMM-AGE to accurately understand an individual's immune status, providing increased information for accurate prediction and management of risks. This new capability has major implications for drug development, including the design of future vaccine trials and re-evaluating past vaccine trials.
A new AI model has been developed to translate mouse model data to human disease conditions, increasing the accuracy of extrapolation by up to 50%. The model, known as Found In Translation (FIT), has been tested on 28 different human diseases and uncovered novel disease-associated genes.
Researchers at CytoReason used machine learning to analyze melanoma biopsies, identifying adipocytes as potential regulators of the tumor microenvironment. The study suggests that these cells may play a previously unreported role in differentiating nivolumab responders from non-responders in ipilimumab-resistant patients.
A new AI model, CytoReason, has created the largest library of inter-cellular communications, mapping over 3,000 previously unlisted cellular interactions. This analysis provides valuable clues for drug development and sheds light on immune system dynamics.